Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Attorneys Assess Impact of FDA’s Final LDT Rule

Some lab clients already signaling concerns that compliance costs will end their LDT offerings

CEO SUMMARY: Publication of the Food and Drug Administration’s final rule on laboratory developed tests (LDTs) is already causing some labs to consider withdrawing their existing LDTs because of compliance costs. Two experienced lab industry attorneys discuss aspects of the LDT rule and what they hear from their clinical laboratory clients. THROUGHOUT THE CLINICAL LABORATORY …

Attorneys Assess Impact of FDA’s Final LDT Rule Read More »

To access this post, you must purchase The Dark Report.



You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.